Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Cortico-Basal syndrome (CBS) are all degenerative brain conditions for which there is not currently any curative treatments.
They are often initially diagnosed as Parkinson’s disease but are very distinct with an approximate survival of 6-7 years from diagnosis. The PROSPECT-M-UK study aims to develop better methods of diagnosing these diseases early in the disease course, as well as tracking progression.
The study team would like to develop new tests that would be helpful in the future for identifying underlying these disease early on. They believe that the development of better diagnostic tools and thorough tracking of disease progression can be improved. This can be done with a greater understanding of the biology behind the diseases and by monitoring it over time.
What does it involve for a participant?
To investigate these aims, we ask our participants to undergo various investigations, including:
• a blood sample
• psychological testing
• a clinical examination by a doctor
There will also be additional investigations, such as an MRI scan, an eye-tracking task and additional psychological testing but these are optional and participants can choose not to participate.
What do you hope the outcomes of the study will be?
The study team are hoping to understand these conditions to help treat people with similar conditions better in the future. They hope that this will help in the design of future drug studies and in the development of new treatments.
Where is the study based and who can take part?
There are a number of sites in the UK that are recruiting patient participants for this study. However this study is only looking for people unaffected by neurological disease to act as a ‘healthy control’ comparison group.
You can see if you are eligible for this study, as well as others around the nation, by logging into your Join Dementia Research account.
Not registered with Join Dementia Research? Why not sign up today?